1. Home
  2. GRAF vs YMAB Comparison

GRAF vs YMAB Comparison

Compare GRAF & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRAF
  • YMAB
  • Stock Information
  • Founded
  • GRAF 2021
  • YMAB 2015
  • Country
  • GRAF United States
  • YMAB United States
  • Employees
  • GRAF N/A
  • YMAB N/A
  • Industry
  • GRAF
  • YMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRAF
  • YMAB Health Care
  • Exchange
  • GRAF NYSE
  • YMAB Nasdaq
  • Market Cap
  • GRAF 294.4M
  • YMAB 192.4M
  • IPO Year
  • GRAF 2024
  • YMAB 2018
  • Fundamental
  • Price
  • GRAF $10.47
  • YMAB $4.37
  • Analyst Decision
  • GRAF
  • YMAB Buy
  • Analyst Count
  • GRAF 0
  • YMAB 11
  • Target Price
  • GRAF N/A
  • YMAB $17.55
  • AVG Volume (30 Days)
  • GRAF 5.1K
  • YMAB 197.6K
  • Earning Date
  • GRAF 01-01-0001
  • YMAB 08-11-2025
  • Dividend Yield
  • GRAF N/A
  • YMAB N/A
  • EPS Growth
  • GRAF N/A
  • YMAB N/A
  • EPS
  • GRAF 0.32
  • YMAB N/A
  • Revenue
  • GRAF N/A
  • YMAB $88,658,000.00
  • Revenue This Year
  • GRAF N/A
  • YMAB N/A
  • Revenue Next Year
  • GRAF N/A
  • YMAB $15.15
  • P/E Ratio
  • GRAF $32.44
  • YMAB N/A
  • Revenue Growth
  • GRAF N/A
  • YMAB 4.92
  • 52 Week Low
  • GRAF $9.03
  • YMAB $3.55
  • 52 Week High
  • GRAF $11.02
  • YMAB $16.11
  • Technical
  • Relative Strength Index (RSI)
  • GRAF N/A
  • YMAB 45.40
  • Support Level
  • GRAF N/A
  • YMAB $4.26
  • Resistance Level
  • GRAF N/A
  • YMAB $4.62
  • Average True Range (ATR)
  • GRAF 0.00
  • YMAB 0.26
  • MACD
  • GRAF 0.00
  • YMAB -0.03
  • Stochastic Oscillator
  • GRAF 0.00
  • YMAB 21.14

About GRAF GRAF GLOBAL CORP

Graf Global Corp is a blank check company.

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Share on Social Networks: